E-viri
Recenzirano
Odprti dostop
-
Ghosh, Arnab; Barba, Pere; Perales, Miguel‐Angel
British journal of haematology, January 2020, Letnik: 188, Številka: 1Journal Article
Summary Immunotherapy is distinct from traditional chemotherapy in that it acts on immune cells rather than cancer cells themselves. Monoclonal antibodies targeting immune checkpoints on T cells – CTLA‐4 and PD‐1 – and PD‐L1 on the cells of immune microenvironment are now approved for clinical use in several solid tumors and hematological malignancies. This article provides a general overview of the use of checkpoint inhibitors in hematologic malignancies with a special focus in acute myeloid leukemia.
